Cosman, F., Cauley, J.A., Eastell, R., Boonen, S., Palermo, L., Reid, I.R., et al. (2014) Reassessment of Fracture Risk in Women after 3 Years of Treatment with Zoledronic Acid: When Is It Reasonable to Discontinue Treatment? The Journal of Clinical Endocrinology & Metabolism, 99, 4546-4554.
https://doi.org/10.1210/jc.2014-1971

has been cited by the following article:

• TITLE: Bisphosphonates Zoledronate and Alendronate for the Management of Postmenopausal Osteoporosis

  AUTHORS: IsraaIsraa Ahmed Radwan, Nahed Sedky Korany, Bassant Adel Ezzat

  KEYWORDS: Bisphosphonates, Alendronate, Zoledronate, Postmenopausal Osteoporosis

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.7 No.5, May 10, 2018

  ABSTRACT: Bisphosphonates are among the most frequently used antiresorptive drugs for the management of postmenopausal osteoporosis. We review here two of the commonly used bisphosphonates zoledronate and alendronate.